13F-HR filed by NEA Management Company, LLC
NEA Management Company, LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 44 holding rows worth $1,500,441,462.
- Accession
- 0001012975-24-000103
- Filer
- CIK 1512848
- Filed
- 2024-02-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 44 entries on the cover page, a total value of $1,500,441,462 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,500,441,462 with VALUE read as dollars as filed, 13F file number 028-14302. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| COURSERA INC COM | 22266M104 | Stock | 12,867,769 | $249,248,686 | dollars as filed | |
| ARCELLX INC COMMON STOCK | 03940C100 | Stock | 3,745,262 | $207,862,041 | dollars as filed | |
| RHYTHM PHARMACEUTICALS INC | 76243J105 | COM | 2,909,956 | $133,770,677 | dollars as filed | |
| SAVARA INC | 805111101 | COM | 24,471,264 | $115,014,941 | dollars as filed | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 5,108,563 | $111,024,890 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 1,587,854 | $99,399,660 | dollars as filed | |
| CVRX INC | 126638105 | COMMON STOCK | 2,370,542 | $74,529,841 | dollars as filed | |
| GERON CORP | 374163103 | COM | 22,776,409 | $48,058,223 | dollars as filed | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 7,692,298 | $43,461,484 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 1,072,936 | $41,140,658 | dollars as filed | |
| NEXTNAV INC | 65345N106 | COMMON STOCK | 8,189,156 | $36,441,744 | dollars as filed | |
| AURINIA PHARMACEUTICALS INC COM | 05156V102 | Stock | 3,969,834 | $35,688,808 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 3,568,781 | $23,553,955 | dollars as filed | |
| NEUEHEALTH INC | 10920V404 | COM NEW | 2,726,917 | $19,862,942 | dollars as filed | |
| SAGIMET BIOSCIENCES INC A | 786700104 | COMMON STOCK | 3,850,275 | $18,781,641 | dollars as filed | |
| CELCUITY INC | 15102K100 | COM | 1,250,001 | $18,212,525 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 1,960,169 | $17,896,343 | dollars as filed | |
| ALLAKOS INC | 01671P100 | COM | 6,147,260 | $16,782,020 | dollars as filed | |
| ZEROFOX HLDGS INC | 98955G103 | COMMON | 18,068,513 | $15,719,606 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 11,370,376 | $15,236,304 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 15,838,009 | $14,452,183 | dollars as filed | |
| ADAPTIMMUNE THERAPEUTICS PLC | 00653A107 | SPONDS ADR | 17,079,778 | $13,544,624 | dollars as filed | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 14,986,793 | $12,566,426 | dollars as filed | |
| BLACK DIAMOND THERAPEUTICS I | 09203E105 | COM | 4,448,757 | $12,501,007 | dollars as filed | |
| Tuya Inc | 90114C107 | COM | 4,934,640 | $11,349,672 | dollars as filed | |
| SYNLOGIC INC | 87166L209 | COM | 2,922,774 | $11,252,673 | dollars as filed | |
| GLYCOMIMETICS INC | 38000Q102 | COM | 4,764,440 | $11,244,079 | dollars as filed | |
| DESKTOP METAL INC | 25058X105 | COM CL A | 14,407,594 | $10,813,594 | dollars as filed | |
| INOZYME PHARMA INC | 45790W108 | COM | 2,437,689 | $10,384,555 | dollars as filed | |
| CHAMPIONS ONCOLOGY INC | 15870P307 | COM NEW | 1,713,720 | $9,630,935 | dollars as filed | |
| RENEO PHARMACEUTICALS INC | 75974E103 | COM | 4,785,494 | $7,656,790 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 1,462,586 | $6,605,038 | dollars as filed | |
| MARKER THERAPEUTICS INC | 57055L206 | COM NEW | 1,071,428 | $5,892,854 | dollars as filed | |
| BUZZFEED INC CL A NEW | 12430A102 | Stock | 15,333,892 | $3,833,473 | dollars as filed | |
| LEXICON PHARMACEUTICALS INC | 528872302 | COMMON STOCK | 2,382,286 | $3,644,898 | dollars as filed | |
| Senti Biosciences, Inc. | 81726A100 | Common Stock | 4,426,151 | $2,921,260 | dollars as filed | |
| AFFIMED N V | N01045108 | COM | 4,426,488 | $2,766,555 | dollars as filed | |
| REGULUS THERAPEUTICS INC | 75915K200 | COM NEW | 1,945,579 | $2,490,341 | dollars as filed | |
| MYND AI INC | 628988107 | SPON ADS | 23,642,711 | $1,816,256 | dollars as filed | |
| ACRIVON THERAPEUTICS INC | 004890109 | CMN | 430,252 | $1,287,333 | dollars as filed | |
| IKENA ONCOLOGY INC | 45175G108 | COM | 570,050 | $1,122,999 | dollars as filed | |
| WHEELS UP EXPERIENCE INC | 96328L205 | COM CL A | 106,126 | $364,009 | dollars as filed | |
| SURF AIR MOBILITY IN EQUCLASS EQUITY | 868927104 | COM | 220,209 | $307,191 | dollars as filed | |
| ADDEX THERAPEUTICS LTD | 00654J206 | SPONSORED ADS | 9,000 | $305,728 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001012975-24-000103 | this filing | 2024-02-14 | acceptance time not in the bulk data set |